Literature DB >> 32858051

Comparison of plasma etonogestrel concentrations sampled from the contralateral-to-implant and ipsilateral-to-implant arms of contraceptive implant users.

Alida M Gertz1, Ian J Bishop2, Boikhutso Simon3, Kwana Lechiile4, Opelo Badubi3, Aamirah Mussa3, Carolyn L Westhoff2, Chelsea Morroni5.   

Abstract

OBJECTIVE: To compare plasma etonogestrel concentrations sampled from the contralateral- versus ipsilateral-to-implant arm. STUDY
DESIGN: Sub-analysis of a cross-sectional study in Botswana in 33 participants who provided contralateral and ipsilateral blood samples.
RESULTS: Plasma etonogestrel concentrations in contralateral and ipsilateral specimens were highly correlated (correlation coefficient = 0.99; p < 0.0001). Bland-Altman analysis of agreement showed that etonogestrel levels were on average 5.9 pg/mL higher (2.1%) in ipsilateral compared to contralateral specimens (95% confidence interval: -4.1, 15.9 pg/mL).
CONCLUSIONS: We found no meaningful differences in plasma etonogestrel concentrations between samples taken from the contralateral- versus ipsilateral-to-implant arm. IMPLICATIONS: Our data suggest that etonogestrel plasma concentrations are unlikely to be meaningfully different between samples drawn from the ipsilateral- versus the contralateral-to-implant arms in etonogestrel contraceptive implant users.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Contraceptive implant; Contralateral arm; Etonogestrel; Ipsilateral arm; Pharmacokinetics

Year:  2020        PMID: 32858051      PMCID: PMC8232040          DOI: 10.1016/j.contraception.2020.08.011

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  9 in total

Review 1.  Development of controlled release systems over the past 50years in the area of contraception.

Authors:  David R Friend
Journal:  J Control Release       Date:  2015-12-28       Impact factor: 9.776

2.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

3.  The pharmacodynamics and efficacy of Implanon. An overview of the data.

Authors:  H B Croxatto; L Mäkäräinen
Journal:  Contraception       Date:  1998-12       Impact factor: 3.375

4.  Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.

Authors:  Catherine A Chappell; Mohammed Lamorde; Shadia Nakalema; Beatrice A Chen; Hope Mackline; Sharon A Riddler; Susan E Cohn; Kristin M Darin; Sharon L Achilles; Kimberly K Scarsi
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.177

5.  Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.

Authors:  Carolina S Vieira; Maria V Bahamondes; Roberto M de Souza; Milena B Brito; Tatiana R Rocha Prandini; Eliana Amaral; Luis Bahamondes; Geraldo Duarte; Silvana M Quintana; Carolina Scaranari; Rui A Ferriani
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-01       Impact factor: 3.731

6.  Plasma levels of levonorgestrel in women during longterm use of norplant.

Authors:  H B Croxatto; S Díaz; P Miranda; K Elamsson; E D Johansson
Journal:  Contraception       Date:  1981-02       Impact factor: 3.375

7.  A UPLC-MS/MS method for therapeutic drug monitoring of etonogestrel.

Authors:  Tiffany Thomas; Kelsey Petrie; Joonho Shim; Kirsten M Abildskov; Carolyn L Westhoff; Serge Cremers
Journal:  Ther Drug Monit       Date:  2013-12       Impact factor: 3.681

8.  Levonorgestrel plasma levels during continuous administration with different models of subdermal implants.

Authors:  F Alvarez; V Brache; A Faundes; E D Johansson; V Odlind; H Nash
Journal:  Contraception       Date:  1983-02       Impact factor: 3.375

9.  Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-based antiretroviral therapy.

Authors:  Ian J Bishop; Alida M Gertz; Boikhutso Simon; Leabaneng Tawe; Kwana Lechiile; Serena Liu; Nicholas Teodoro; Aamirah Mussa; Ava Avalos; Sifelani Malima; Tshego Maotwe; Lesego Mokganya; Carolyn L Westhoff; Chelsea Morroni
Journal:  Contraception       Date:  2020-05-07       Impact factor: 3.375

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.